ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals, Inc. (SPRY) is a healthcare company (biotechnology) based in the United States. The share price is $3.71, up 3.20% on the day, which values the company at $372.46M. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.

Key facts

Share price
$3.71+3.20% today
Market value
$372.46M
Funk Score
44/100
Against its own history
Well below its usual priceusual price $12.25
200-week average
$9.2960% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

ARS Pharmaceuticals, Inc. in more detail

SPRY trades at -4.5× next year's expected earnings, 3.0× sales. Measured against its own history, the price is 70% below what its usual multiples would imply ($12.25) — well below its usual price. It sits 60% below its 200-week average of $9.29.

Its Funk Score is 44 out of 100 (financial strength 3.3, profitability 2.9, growth 6.3, value 5.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Beneish M-score flags the accounts.

2 of the superinvestors tracked here hold SPRY, including Peter Kolchinsky (0.8% of the portfolio), Dan Loeb (0.2% of the portfolio).

Superinvestors holding SPRY

2 of the investors tracked here report a position in their latest 13F filing.

ARS Pharmaceuticals, Inc. (SPRY): questions and answers

What is ARS Pharmaceuticals, Inc.'s market cap?

ARS Pharmaceuticals, Inc. is valued at $372.46M at a share price of $3.71.

Is SPRY overvalued or undervalued?

Against its own history, SPRY is well below its usual price: the price is 70% below the $12.25 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is SPRY above its 200-week moving average?

No. SPRY is 60.1% below its 200-week average of $9.29. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is ARS Pharmaceuticals, Inc. growing?

Over the last three fiscal years ARS Pharmaceuticals, Inc.'s revenue grew 300.1% a year.

Does SPRY pay a dividend?

ARS Pharmaceuticals, Inc. does not currently pay a regular dividend.

Which famous investors own SPRY?

In their latest quarterly filings, Peter Kolchinsky (0.8% of the portfolio), Dan Loeb (0.2% of the portfolio) hold SPRY. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “ARS Pharmaceuticals, Inc. (SPRY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/SPRY

Underlying data: Yahoo Finance; company filings with the SEC.